A risk score, titled PREDICT-SID (Prediction of secondary immunodeficiency in MGUS and NDMM), was developed based on four primary risk factors identified in the study: induction of MM therapy, ECOG, ISS stage, and CD8+ TEMRAs. The gene discussed is CD8A; the disease is Miyoshi myopathy.